CONMED Corporation, a medical technology company that makes surgical instruments and devices, saw its stock fall about 5.1% on Monday after a Wall Street analyst downgraded the shares and warned that the company could underperform its rivals over the next year.
Bank of America Securities lowered its rating on CONMED to underperform from neutral, a bearish call that signals the bank expects the stock to trail the broader market or its industry peers. The downgrade came with a reduced organic growth forecast for 2027, now pegged at 4.5%, down from the bank's earlier estimate.
Why the downgrade?
BofA's move reflects a growing belief that the medtech sector is becoming more competitive and that CONMED may struggle to keep pace. The bank cited a tougher operating environment, where pricing pressures, slower procedure volumes, and rising costs could squeeze margins. For a company like CONMED, which specializes in orthopedic surgery, sports medicine, and general surgery products, even a small slowdown in growth can have outsized effects on investor sentiment.
The downgrade is part of a broader trend on Wall Street, where analysts are reassessing medtech companies as the post-pandemic procedure boom fades. Earlier this year, RBC noted that Smith & Nephew faces a tight path to its 2026 growth target, highlighting similar pressures across the sector.
What the numbers mean
Organic growth measures a company's revenue increase from its existing operations, excluding the effects of acquisitions, currency fluctuations, or one-time items. A 4.5% organic growth forecast for 2027 is below what many medtech companies have historically delivered, and it suggests that CONMED may be losing market share or facing headwinds that its peers are better positioned to handle.
Investors often watch these forecasts closely because they reflect analysts' views on a company's competitive position. When a bank cuts its growth outlook, it can signal that the company's products are not gaining traction as quickly as expected, or that the overall market is slowing.
What it means for investors
For everyday investors, the downgrade is a reminder that even established medtech companies can face periods of underperformance. CONMED's 5.1% drop on Monday was a sharp reaction, but it is not unusual for stocks to move significantly on analyst downgrades, especially when they come from a major firm like Bank of America.
Investors should consider that the medtech sector is cyclical and tied to hospital budgets, surgical volumes, and insurance reimbursement rates. When those factors turn less favorable, companies like CONMED can see their growth slow. The downgrade does not mean CONMED is in trouble, but it does suggest that the next year may be more challenging than previously thought.
Other medtech companies have also faced scrutiny. UBS recently said Reckitt's 2026 growth outlook cools, and Danone's Q2 sales growth is expected to accelerate, but the broader picture for healthcare-related firms remains mixed.
What to watch next
Investors will be watching CONMED's next earnings report for signs of whether the company can meet or beat the lowered expectations. They will also look for any commentary from management about procedure volumes, pricing, and new product launches. If CONMED can show that it is gaining share in key markets or that its pipeline of new devices is strong, the stock could recover. But if the headwinds persist, the underperform rating may prove prescient.
For now, the downgrade adds to a cautious tone in the medtech space, and investors may want to keep an eye on how other companies in the sector fare. BofA has also lowered targets on other companies, but remains bullish on some, showing that the bank is picking winners and losers rather than turning negative on the entire sector.
